<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0005374"><a href="http://purl.obolibrary.org/obo/MONDO_0005374">MONDO:0005374</a></h3>
<p><strong>Label:</strong> myeloproliferative disorder</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0019438">MONDO:0019438</a> (AL amyloidosis), <a href="http://purl.obolibrary.org/obo/MONDO_0013794">MONDO:0013794</a> (thrombocythemia 3), <a href="http://purl.obolibrary.org/obo/MONDO_0011173">MONDO:0011173</a> (thrombocythemia 2), <a href="http://purl.obolibrary.org/obo/MONDO_0009692">MONDO:0009692</a> (primary myelofibrosis), <a href="http://purl.obolibrary.org/obo/MONDO_0009693">MONDO:0009693</a> (multiple myeloma), <a href="http://purl.obolibrary.org/obo/MONDO_0019454">MONDO:0019454</a> (refractory anemia with excess blasts), <a href="http://purl.obolibrary.org/obo/MONDO_0019111">MONDO:0019111</a> (familial thrombocytosis), <a href="http://purl.obolibrary.org/obo/MONDO_0019452">MONDO:0019452</a> (chronic myeloproliferative disease, unclassifiable), <a href="http://purl.obolibrary.org/obo/MONDO_0008554">MONDO:0008554</a> (thrombocythemia 1), <a href="http://purl.obolibrary.org/obo/MONDO_0015691">MONDO:0015691</a> (hypereosinophilic syndrome), <a href="http://purl.obolibrary.org/obo/MONDO_0020312">MONDO:0020312</a> (atypical chronic myeloid leukemia), <a href="http://purl.obolibrary.org/obo/MONDO_0005029">MONDO:0005029</a> (essential thrombocythemia), <a href="http://purl.obolibrary.org/obo/MONDO_0007896">MONDO:0007896</a> (acute monocytic leukemia), <a href="http://purl.obolibrary.org/obo/MONDO_0020076">MONDO:0020076</a> (myeloproliferative neoplasm), <a href="http://purl.obolibrary.org/obo/MONDO_0011996">MONDO:0011996</a> (chronic myelogenous leukemia), <a href="http://purl.obolibrary.org/obo/MONDO_0005171">MONDO:0005171</a> (chronic myeloproliferative disorder), <a href="http://purl.obolibrary.org/obo/MONDO_0017834">MONDO:0017834</a> (secondary hypereosinophilic syndrome), <a href="http://purl.obolibrary.org/obo/MONDO_0013667">MONDO:0013667</a> (myelodysplastic syndrome), <a href="http://purl.obolibrary.org/obo/MONDO_0011118">MONDO:0011118</a> (acute myeloid leukemia),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://www.orpha.net/ORDO/Orphanet_86839">Orphanet:86839</a>, <a href="http://purl.obolibrary.org/obo/OMIM_187950">OMIM:187950</a>, <a href="http://www.orpha.net/ORDO/Orphanet_52688">Orphanet:52688</a>, <a href="http://purl.obolibrary.org/obo/OMIM_151380">OMIM:151380</a>, <a href="http://purl.obolibrary.org/obo/OMIM_601977">OMIM:601977</a>, <a href="http://www.orpha.net/ORDO/Orphanet_85443">Orphanet:85443</a>, <a href="http://www.orpha.net/ORDO/Orphanet_86830">Orphanet:86830</a>, <a href="http://www.orpha.net/ORDO/Orphanet_3318">Orphanet:3318</a>, <a href="http://www.orpha.net/ORDO/Orphanet_519">Orphanet:519</a>, <a href="http://www.orpha.net/ORDO/Orphanet_98836">Orphanet:98836</a>, <a href="http://www.orpha.net/ORDO/Orphanet_514">Orphanet:514</a>, <a href="http://purl.obolibrary.org/obo/OMIM_254500">OMIM:254500</a>, <a href="http://www.orpha.net/ORDO/Orphanet_71493">Orphanet:71493</a>, <a href="http://www.orpha.net/ORDO/Orphanet_98274">Orphanet:98274</a>, <a href="http://purl.obolibrary.org/obo/OMIM_300331">OMIM:300331</a>, <a href="http://purl.obolibrary.org/obo/OMIM_601626">OMIM:601626</a>, <a href="http://www.orpha.net/ORDO/Orphanet_29073">Orphanet:29073</a>, <a href="http://purl.obolibrary.org/obo/OMIM_614286">OMIM:614286</a>, <a href="http://purl.obolibrary.org/obo/OMIM_131440">OMIM:131440</a>, <a href="http://purl.obolibrary.org/obo/OMIM_614521">OMIM:614521</a>, <a href="http://purl.obolibrary.org/obo/OMIM_254450">OMIM:254450</a>, <a href="http://www.orpha.net/ORDO/Orphanet_168956">Orphanet:168956</a>, <a href="http://www.orpha.net/ORDO/Orphanet_824">Orphanet:824</a>, <a href="http://www.orpha.net/ORDO/Orphanet_314701">Orphanet:314701</a>, <a href="http://www.orpha.net/ORDO/Orphanet_98824">Orphanet:98824</a>, <a href="http://purl.obolibrary.org/obo/OMIM_608232">OMIM:608232</a>, <a href="http://www.orpha.net/ORDO/Orphanet_521">Orphanet:521</a>, <a href="http://www.orpha.net/ORDO/Orphanet_314962">Orphanet:314962</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0010978">HP:0010978</a> (Abnormality of immune system physiology))) 46.69%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0011121">HP:0011121</a> (Abnormality of skin morphology))) 45.15%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0000271">HP:0000271</a> (Abnormality of the face))) 44.94%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0000234">HP:0000234</a> (Abnormality of the head))) 44.94%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0012638">HP:0012638</a> (Abnormality of nervous system physiology))) 43.77%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0001574">HP:0001574</a> (Abnormality of the integument))) 42.85%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0000951">HP:0000951</a> (Abnormality of the skin))) 42.85%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0000707">HP:0000707</a> (Abnormality of the nervous system))) 42.85%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0004377">HP:0004377</a> (Hematological neoplasm) 41.84%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) 40.40%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0000004">HP:0000004</a> (null))) 40.40%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0000003">HP:0000003</a> (Multicystic kidney dysplasia))) 40.40%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002715">HP:0002715</a> (Abnormality of the immune system) and <a href="http://purl.obolibrary.org/obo/HP_0004377">HP:0004377</a> (Hematological neoplasm) 40.37%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000005">HP:0000005</a> (Mode of inheritance) and <a href="http://purl.obolibrary.org/obo/HP_0004377">HP:0004377</a> (Hematological neoplasm) 38.54%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001871">HP:0001871</a> (Abnormality of blood and blood-forming tissues) 36.80%</li>
</ul>
</body>
</html>
